We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Reaction Biology Corporation today announced that it has been awarded an SBIR grant from the National Cancer Institute to create a new kinase profiling and high throughput screening method using radioisotopes and microarrays.
Tuesday, CEL-SCI Corp., a biotechnology company, released a letter to its shareholders informing the share holders that the company has bought another 87,600 shares of CEL-SCI in the open market.
Hana Biosciences, a biopharmaceutical company focused on advancing cancer care, will join the Russell 3000 Index and the Russell Microcap Index when the Russell Investment Group reconstitutes its family of U.S. Indexes on June 30, 2006.
A Baltimore biotechnology company has changed its name to better reflect its shift from a drug development firm to one helping customers commercialize new therapies.
Israel-based drugmaker CureTech has finalized an agreement in which Teva Pharmaceutical has received an option to invest $22 million in the company, in addition to a $6 million investment announced several months ago.
GlaxoSmithKline's (GSK) Wellbutrin XL has been approved to be the first drug for treating patients with a history of seasonal affective disorder (SAD), the FDA announced.
The U.S. Supreme Court has rejected a request by GlaxoSmithKline (GSK) to review an appeals court ruling allowing Apotex to market a generic version of GSK's antidepressant Paxil.